<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978755</url>
  </required_header>
  <id_info>
    <org_study_id>C101</org_study_id>
    <nct_id>NCT02978755</nct_id>
  </id_info>
  <brief_title>First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers</brief_title>
  <official_title>Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GamaMabs Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GamaMabs Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study, assessing the safety profile, the pharmacokinetics and preliminary&#xD;
      antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with&#xD;
      previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor&#xD;
      II) receptor. The primary objective of the study is to determine the GM102 recommended dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMHRII is reexpressed in a subset of gynecological cancers. GM102 is a humanized low fucose&#xD;
      monoclonal antibody with a high affinity to AMHRII receptor. GM102 acts through enhanced&#xD;
      capability to engage immune effector cells (macrophages, natural killer (NK) cells) to&#xD;
      trigger ADCC (antibody dependent cellular cytotoxicity) and phagocytosis of tumor cells.&#xD;
&#xD;
      Patients with gynecological tumors expressing AMHRII receptor on the tumor cells in archived&#xD;
      tissue as determined prior to study entry will be eligible for C101 study.&#xD;
&#xD;
      C101 consists of a phase I part (dose and schedule escalation) and a phase Ib part&#xD;
      (expansion).&#xD;
&#xD;
      The phase I part is designed to determine the recommended phase 2 dose (RP2D) using the&#xD;
      classical 3+3 dose-finding design. In six successive escalating dose cohorts, patients will&#xD;
      receive GM102 infusions every 2 weeks until progression or toxicity. In 4 additional cohorts,&#xD;
      patients will receive GM102 infusions weekly until progression or toxicity and GM102&#xD;
      infusions combined with chemotherapy until progression or toxicity.&#xD;
&#xD;
      A Trial Steering Committee (TSC) will analyze and qualify the toxicities and will provide&#xD;
      recommendations according to the dose administration rules defined in the protocol.&#xD;
&#xD;
      At the end of the phase I part, the RP2D will be determined, taking into account dose&#xD;
      limiting toxicities (DLTs), overall toxicity, pharmacokinetics and pharmacodynamics effects&#xD;
      of GM102.&#xD;
&#xD;
      The Phase Ib part of the study will confirm the tolerance of the selected dose (RP2D) and&#xD;
      will assess antitumoral activity of GM102 in three parallel cohorts of patients with Sex&#xD;
      Cord-Stromal tumors, and AMHRII positive ovarian and cervix cancers. Patients will be treated&#xD;
      until progression or toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>phase 1 escalation GM102 single agent&#xD;
phase 1 escalation GM102 combined with paclitaxel and carboplatin&#xD;
phase 1b: 3 parallel expansion cohorts at the recommended dose of GM102 single agent</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I part: incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib part: incidence of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) at Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration [Cmax]</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate defined as percentage of patients achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) superior to 3 months</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Neoplasm, Gynecologic</condition>
  <arm_group>
    <arm_group_label>GM102 escalating doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 successive cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM102 escalating doses + carboplatin+paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 successive cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM102 recommended dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM102</intervention_name>
    <description>GM102 escalating doses (phase1)</description>
    <arm_group_label>GM102 escalating doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + carboplatin</intervention_name>
    <description>GM102 escalating doses combined with paclitaxel and carboplatin</description>
    <arm_group_label>GM102 escalating doses + carboplatin+paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM102</intervention_name>
    <description>GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)</description>
    <arm_group_label>GM102 recommended dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced, or metastatic recurrent gynecological cancer, for whom no standard&#xD;
             alternative therapy is available, having received at least one line of therapy and&#xD;
             expressing AMHRII on tumor cells.&#xD;
&#xD;
          -  If possible at least one lesion should be identified for 2 biopsies: a baseline biopsy&#xD;
             and an under-treatment biopsy for AMHRII expression and GM102 pharmacodynamics&#xD;
             evaluation.&#xD;
&#xD;
          -  Available tumor block or at least 10 slides from formalin-fixed paraffin-embedded&#xD;
             (FFPE) archival tissue.&#xD;
&#xD;
          -  At least one measurable lesion by RECIST (Response Evaluation Criteria in Solid&#xD;
             Tumors) on screening CT-scan.&#xD;
&#xD;
          -  Written Informed Consent forms.&#xD;
&#xD;
          -  Willing and able to comply with the trial requirements.&#xD;
&#xD;
          -  Covered by healthcare insurance in accordance with local requirements.&#xD;
&#xD;
        For phase 1b, only patients with either Sex cord stromal tumors or epithelial ovarian&#xD;
        cancer or cervix cancer will be eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 1&#xD;
&#xD;
          -  Life expectancy &lt; 12 weeks.&#xD;
&#xD;
          -  Known or symptomatic brain metastasis (other than totally resected or previously&#xD;
             irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy.&#xD;
&#xD;
          -  Concurrent chronic corticosteroid treatment.&#xD;
&#xD;
          -  Known severe anaphylactic or other hypersensitivity reactions secondary to a prior&#xD;
             exposure to human antibodies or to any protein product.&#xD;
&#xD;
          -  Washout period before treatment initiation: &lt; 3 weeks or 5 times the half-life,&#xD;
             whichever is shorter, for prior antitumor therapy (small molecules and/or&#xD;
             antibody-drug conjugates, radiotherapy) or 6 weeks for monoclonal antibodies.&#xD;
&#xD;
          -  Any active concomitant malignancy.&#xD;
&#xD;
          -  Serious concomitant illness e.g. active infection requiring systemic antibiotic,&#xD;
             antifungal or antiviral drug, or physical examination or laboratory abnormalities,&#xD;
             that, in the opinion of the Investigator, would compromise protocol objectives.&#xD;
&#xD;
          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.0 x 10E9/L or haemoglobin &lt; 9.0&#xD;
             g/dL or platelet count &lt; 100 x 10E9/L.&#xD;
&#xD;
          -  Poor organ function as defined by any one of the following: left ventricular ejection&#xD;
             fraction ≤ 40%, serum creatinine &gt; 1.5 x upper limit of normal (ULN), total bilirubin&#xD;
             &gt; 1.5 x ULN, AST and ALT&gt; 2.5 x ULN in the absence of liver metastasis or &gt; 5 x ULN in&#xD;
             case of documented liver metastasis.&#xD;
&#xD;
          -  Non-resolution of any prior treatment related toxicity to &lt; Grade 2, except for&#xD;
             alopecia according to National Cancer Institute-Common Terminology Criteria for&#xD;
             Adverse Events (NCI-CTCAE) v4.03.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patient with reproductive potential who do not agree to use an accepted effective&#xD;
             method of contraception - investigator's judgment - during the study period and for at&#xD;
             least 4 months following completion of study treatment.&#xD;
&#xD;
          -  Patient participating in another clinical trial investigating a treatment during the&#xD;
             study and within 30 days prior to first study treatment administration.&#xD;
&#xD;
          -  Patient deprived of her liberty by a judicial or administrative decision, patient&#xD;
             admitted to a hospital, social institution or who is under a measure of legal&#xD;
             protection, patient hospitalized without consent or who is in an emergency situation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Leary, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy center, Villejuif, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

